ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · ESMO Open · 2026-06-12

Exploratory secondary analysis of a phase 3 trial (n=700) in advanced urothelial carcinoma after platinum chemotherapy: avelumab maintenance plus BSC vs BSC alone had OS HR 0.77 (95% CI 0.49-1.21) in 122 with high BMI and 0.60 (0.37-0.95) in 114 with diabetes.

Secondary analysisn = 700
Aragon-Ching et al. Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus
Urology · World J Urol · 2026-01-13

Post hoc analysis of the phase 2 AURA trial (88 patients with muscle-invasive bladder cancer, radical cystectomy): complications 52%; major complications were more frequent after neoadjuvant chemo-immunotherapy than avelumab alone (21.2% vs 15.4%, p=0.03; non-randomised).

Secondary analysisn = 88
Mjaess et al. Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004)

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.